Picture of Ion Beam Applications SA logo

IBAB — Ion Beam Applications SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

IBA jumps on cyclotron network partnership with Framatome

** Shares in Ion Beam Applications  IBAB.BR  rise 4.3% after
the Belgian healthcare firm announced it would partner with
Framatome to develop cyclotron network 
    ** The two companies will collaborate on building a
Astatine-211 network in Europe and the U.S. with IBA
contributing specialised equipment
    ** "We do like IBA expanding the potential addressable
market for its cyclotrons", ING analysts say in a note, adding
it could leverage technological competitive edge to gain more
value chain in a new industry
    ** ING adds that the Astatine product would complement, not
compete, with firm's radioisotope Actinium, as it can have other
type of cancer treatment application
    ** Astatine is a radioisotope currently being investigated
for its potential in targeted alpha-therapeutic approaches in
oncology

 (Reporting by Mateusz Rabiega)
 ((Mateusz.rabiega@thomsonreuters.com;))

Recent news on Ion Beam Applications SA

See all news